GOLDILOX-TIMI 69 is a Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Trial To Evaluate the Efficacy and Safety of MEDI6570 (a fully human monoclonal antibody against LOX-1) in Participants with a Prior Myocardial Infarction, Persistent Inflammation, and Elevated N-Terminal Prohormone Brain Natriuretic Peptide.
MAIN RESULTS:
Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial
Nat Med 2025;31:3553-9.
GOLDILOX on ClinicalTrials.gov
Contact Us about GOLDILOX